Seres Therapeutics, Inc. (MCRB)
NASDAQ: MCRB · Real-Time Price · USD
7.74
-0.20 (-2.52%)
At close: Jul 2, 2026, 4:00 PM EDT
7.89
+0.15 (1.94%)
After-hours: Jul 2, 2026, 5:17 PM EDT
Seres Therapeutics Revenue
Seres Therapeutics had revenue of $358.00K in the quarter ending March 31, 2026. In the year 2025, Seres Therapeutics had annual revenue of $789.00K.
Revenue (ttm)
$789.00K
Revenue Growth
n/a
P/S Ratio
65.35
Revenue / Employee
$17,379
Employees
66
Market Cap
74.95M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 789.00K | - | - |
| Dec 31, 2024 | - | - | - |
| Dec 31, 2023 | - | - | - |
| Dec 31, 2022 | - | - | - |
| Dec 31, 2021 | 144.93M | 111.71M | 336.33% |
| Dec 31, 2020 | 33.22M | -1.29M | -3.74% |
| Dec 31, 2019 | 34.51M | 6.24M | 22.07% |
| Dec 31, 2018 | 28.27M | -3.83M | -11.94% |
| Dec 31, 2017 | 32.10M | 10.33M | 47.48% |
| Dec 31, 2016 | 21.77M | - | - |
| Dec 31, 2015 | - | - | - |
| Dec 31, 2014 | - | - | - |
| Dec 31, 2013 | - | - | - |
| Dec 31, 2012 | - | - | - |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Heron Therapeutics | 150.71M |
| Gossamer Bio | 55.54M |
| MindWalk Holdings | 20.70M |
| BeyondSpring | 1.88M |
| eXoZymes | -700.00 |
MCRB News
- 8 days ago - Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres' SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis - GlobeNewsWire
- 10 days ago - Seres Therapeutics initiated with a Buy at H.C. Wainwright - TheFly
- 4 weeks ago - Seres Therapeutics announces two transactions - TheFly
- 4 weeks ago - Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 - GlobeNewsWire
- 6 weeks ago - Seres Therapeutics Transcript: H.C. Wainwright 4th Annual BioConnect Investor Conference - Transcripts
- 7 weeks ago - Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference - GlobeNewsWire
- 2 months ago - Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates - GlobeNewsWire
- 2 months ago - Seres Therapeutics Earnings release: Q1 2026 - Filings